Capricor Therapeutics to Present at Upcoming Investor and Scientific Conferences

Core Insights - Capricor Therapeutics is focused on developing cell and exosome-based therapeutics for rare diseases, with a lead program for deramiocel aimed at treating Duchenne muscular dystrophy (DMD) [1][3] - The company will present updates on its progress and scientific developments at various upcoming investor and scientific conferences [2] Company Overview - Capricor Therapeutics, Inc. (NASDAQ: CAPR) is dedicated to advancing innovative therapies for rare diseases, with deramiocel (CAP-1002) being a key product candidate currently in Phase 3 clinical development for DMD [3] - Deramiocel is an allogeneic cardiac-derived cell therapy that has shown immunomodulatory, antifibrotic, and regenerative properties in preclinical and clinical studies [3] - The company is also developing its proprietary StealthX™ platform for exosome technology, targeting applications in vaccinology and the delivery of therapeutics [3] Commercial Agreements - Capricor has entered into an exclusive agreement with Nippon Shinyaku Co., Ltd. for the commercialization and distribution of deramiocel in the United States and Japan, pending regulatory approval [5]